Clinical value beyond price alone: biosimilars improve patient access to treatment

Immune-mediated inflammatory diseases (IMIDs) are chronic conditions characterised by altered immune regulation causing chronic inflammation in bodily organs or systems. Despite the clinical benefits of biological medicines for IMIDs, the cost of these medicines is relatively high. The high cost of biologics, combined with a stringent regulatory environment in Europe, have created several patient needs, such as access to treatment for IMIDs. As many biologics have now reached patent expiry, several cost-effective biosimilars have been developed and are available for patients with IMIDs.

Biosimilars have enabled lower-cost biologics to enter the market, thereby reducing healthcare spending and releasing budgets that can be reallocated to other disease areas or healthcare services. Cost savings from biosimilars could lead to parity between reimbursement criteria and European clinical guidelines, potentially improving early access to treatments and outcomes in some patients with IMIDs. Improved access can reduce costly surgery and hospitalisations in patients who have benefited from earlier access to biologics.

It is hoped that biosimilars will continue to reduce inequities in the use of biologic medicines for IMIDs and potentially to meet patient needs associated with biologics.


Login to Medthority, or register an account, to read the entire article.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.